Valproic Acid Antibody (Mouse Monoclonal)

From: $250.00

Mouse monoclonal antibody to valproic acid (a drug used to treat migraines, seizures and bipolar disorders). Size: 0.1 mg. Five clones are available for sale individually or as a set: 7C8, 3B9, 9D1, 5C11, 6H7. Antibodies can be used in ELISA and other immunoassays and immuno-detection methods. Bulk pricing and biotinylation services are available.

Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST).

Clone Catalog #
7C8 A2010004-7C8
3B9 A2010004-3B9
9D1 A2010004-9D1
5C11 A2010004-5C11
6H7 A2010004-6H7
5-Clone Set A2010004-SET
Clear
SKU: A2010004 Category: Tags: ,

Description

Monoclonal Antibody to Valproic Acid. 5 different clones are available.

Product Data Sheet
Catalog # A2010004-7C8

A2010004-3B9

A2010004-9D1

A2010004-5C11

A2010004-6H7

A2010004-SET

Size 0.1 mg
Other Names Mab to Valproic Acid, antibody to Valproic Acid
Host Mouse
Concentration 1.0 mg/mL
Purity >90% (protein A column)
Storage -20°C. Avoid repeated freeze/thaw cycles.
Supplied as Liquid solution
Buffer 1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide.
Keywords Valproic acid, mouse monoclonal antibody

 

References

  • Valproic acid enhances the viability of random pattern skin flaps: involvement of enhancing angiogenesis and inhibiting oxidative stress and apoptosis. Wu H, Ding J, Wang L, Lin J, Li S, Xiang G, Jiang L, Xu H, Gao W, Zhou K. Drug Des Devel Ther. 2018 Nov 16;12:3951-3960.
  • Valproicacid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Nau H, Hauck RS, Ehlers K. Pharmacol Toxicol. 1991 Nov;69(5):310-21.
  • Evaluation of the mood-stabilizing agent valproicacid as a preventative for toxoplasmosis in mice and activity against tissue cysts in mice. Goodwin DG, Strobl J, Mitchell SM, Zajac AM, Lindsay DS. J Parasitol. 2008 Apr;94(2):555-7.
  • Valproicacid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproicacid-induced neural tube defects. Defoort EN, Kim PM, Winn LM. Mol Pharmacol. 2006 Apr;69(4):1304-10.
  • Derivatization oriented strategy for enhanced detection of valproicacid and its metabolites in human plasma and detection of valproicacid induced reactive oxygen species associated protein modifications by mass spectrometry. Wu CY, Lu CY. J Chromatogr A. 2014 Dec 29;1374:14-22.
  • Acute valproicacid overdose. Clinical course and pharmacokinetic disposition of valproicacid and metabolites. Dupuis RE, Lichtman SN, Pollack GM. Drug Saf. 1990 Jan-Feb;5(1):65-71.
  • Effects of long-term valproic acid treatment on hematological and biochemical parameters in adolescent psychiatric inpatients: a retrospective naturalistic study. Amitai M, Sachs E, Zivony A, Remez R, Ben Baruch R, Amit BH, Kronenberg S, Apter A, Shoval G, Weizman A, Zalsman G. Int Clin Psychopharmacol. 2015 Sep;30(5):241-8.

Material Safety Data Sheet